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Background: Osteoarthritis of the first metatarsophalangeal joint (hallux rigidus) leads to pain and poor function
and mobility. Arthrodesis is the gold standard treatment for end-stage disease. Total joint arthroplasties have been
attempted, but early loosening has been attributed to dorsally directed shear forces on the metatarsal component.
Metallic proximal phalangeal hemiarthroplasty theoretically avoids this. Whilst early results are promising, no
comparative trials exist comparing this to arthrodesis.
Methods/Design: The primary objectives are to determine the range of outcome scores between the two
treatment arms (to inform a power calculation). Outcome measures will include the MOXFQ, AOFAS-Hallux and
EuroQol EQ-5D-5 L. Secondary objectives are to determine the accrual rate, dropout rate and trial acceptability to
both patients and surgeons. These data will allow the development of a larger trial with longer follow-up.
This is a prospective randomised controlled single-centre study comparing proximal phalanx hemiarthroplasty
(AnaToemic, Arthrex Ltd., Sheffield, UK) with arthrodesis (15 patients in each arm). Randomisation will be performed
using a 1:1 allocation ratio in blocks of six.
Patients meeting the eligibility criteria will be recruited from three foot and ankle consultant surgeon’s clinics (East
Lancashire Hospitals NHS Trust). If agreeable, informed consent will be obtained before patients are randomised.
The outcome measure scores will be completed pre-operatively and repeated at 6 weeks, 3 months and 12 months.
A radiological review will be performed at 6 weeks and 12 months to determine rates of loosening (hemiarthroplasty)
and union (arthrodesis). Data on length of stay, return to work, complications and re-operation rates will also be
collected.
The analysis will compare the change in outcome scores between treatment groups at all follow-up time points.
Scores will be compared using a Student t-test, adjusting for scores at baseline.
This study will be conducted in accordance with the current revision of the Declaration of Helsinki (1996) and the
ICH-GCP Guideline (International Conference on Harmonisation, Good Clinical Practice, E6(R1), 1996). This study has
been approved by the sponsor, the Trust Research & Development office. Ethical approval has been received from
the National Research Ethics Service (North East: 12/NE/0385 for protocol version 5.3 dated 3 June 2013).
Trial registration: Current Controlled Trials ISRCTN88273654
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First described in 1887, hallux rigidus refers to the symp-
toms of degenerative arthritis of the first metatarsophalan-
geal joint (MTPJ) [1]. It is characterised by pain, loss of
motion, primarily dorsiflexion and periarticular osteo-
phyte formation. More common in females, hallux rigidus
is thought to affect 1 in 45 individuals over the age of
60 years [2]. Trauma is a frequently cited aetiological fac-
tor, especially for unilateral hallux rigidus [3]. Generalised
osteoarthritis and inflammatory arthropathies, such as
rheumatoid arthritis, can also result in hallux rigidus.
Irrespective of the causative factors involved, end-stage
disease results in articular cartilage loss and loss of joint
space. Subsequent pain and loss of motion results in ab-
normal gait patterns and can interfere with simple daily
tasks such as walking and stair climbing [4]. The sever-
ity of hallux rigidus can be classified using the system
suggested by Coughlin and Shurnas [5]. Early disease,
grades 0 to 2, can respond well to non-operative mea-
sures such as non-steroidal anti-inflammatory medica-
tion and footwear modification. Cheilectomy to remove
impinging dorsal osteophytes can also be successful in
early cases as the disease initially affects the dorsal por-
tion of the joint. End-stage disease, grade 3 to 4, does
not, however, respond as well to such measures and
remaining options include joint arthrodesis or arthro-
plasty [6].
First MTPJ arthrodesis is currently considered to be the
gold standard for the treatment of end-stage hallux rigi-
dus, with reported union rates ranging between 90% and
100% [7]. Arthrodesis does, however, predispose the pa-
tient to interphalangeal joint osteoarthritis and the loss of
dorsiflexion can interfere with activities such as kneeling
and squatting, and wearing footwear with raised heels can
be problematic [8,9]. Post-operative rehabilitation can also
be prolonged and there is up to a 10% risk of non-union,
which may require a revision procedure [7]. Thus as an
alternative, arthroplasty of the first MTPJ has been
attempted.
Silicone implants were initially used following their
successful implantation in the hand. Early results were
promising with high rates of patient satisfaction [10].
Unfortunately, problems with silicone wear, osteolysis and
foreign body reactions limited their longevity [11,12]. Sili-
cone has therefore been suggested to be a material not
suitable for first MTPJ replacement due to its poor ability
to withstand the forces encountered.
This led to the development of metallic implants in
both total toe replacement and hemiarthroplasty designs
[13]. Total toe implants have demonstrated good early
patient satisfaction [14]. Early loosening, however, was
once again a problem [14,15]. This is thought to be due
to the large dorsally directed shear forces the metatarsal
implant is exposed to during toe-off [16].Metallic proximal phalangeal hemiarthroplasty (PPH)
may therefore avoid both problems related to silicone
wear and loosening related to the shear forces exerted
on metatarsal head implants. The literature on the re-
sults of these implants is, however, sparse and somewhat
conflicting. Townley and Taranow [17] published the
largest series of 279 PPHs with follow-up ranging from
10 months to 33 years. This retrospective review re-
ported good or excellent results in 95% of subjects.
More recently Sorbie and Saunders [18] published their
series of 23 patients treated with PPH with follow-up
ranging from 34 to 72 months. They report an improve-
ment in AOFAS score from 57 to 88 with no cases of
loosening or osteolysis. In contrast Raikin et al. [19]
found inferior results for PPH compared to arthrodesis.
They conducted a retrospective review of 48 feet, 27
with arthrodeses and 21 with PPHs. Of the arthrodesis
group, 85% were deemed to have had a good outcome
based upon patient-reported satisfaction, versus 60% in
the PPH group, with 5 (24%) of the PPH group requir-
ing re-operation due to loosening. They concluded arth-
rodesis is a more predictable technique for dealing with
hallux rigidus.
The literature is therefore divided regarding the effi-
cacy of PPH for the treatment of hallux rigidus. Studies
to date have all been retrospective in nature. The only
prospective randomised trial so far has compared total
joint arthroplasty versus arthrodesis, and concluded out-
comes for arthrodesis were better than arthroplasty [20].
A similar prospective randomised study therefore is re-
quired to compare outcomes of PPH versus joint arth-
rodesis accurately. We therefore propose a randomised
controlled trial comparing the AnaToemic PPH (Arthrex
Ltd., Sheffield, UK) to first MTPJ arthrodesis. This pros-
thesis shares similar design features to the BioPro First
MPJ Hemi Implant (BioPro, Michigan, USA) but has a
better cost profile. Early results reported by Kissler and
colleagues are promising, with good improvements in
pain scores and revision rates comparable to non-union
rates observed with arthrodesis [21].
Methods/Design
This study will run as a prospective single-centre rando-
mised controlled trial with two parallel treatment arms
containing 15 participants each and comparing PPH with
arthrodesis (the current gold standard for the treatment
for hallux rigidus). The primary objective is to determine
the range of improvement in outcome scores following
these procedures. The secondary objective is to determine
the patient recruitment rate, trial dropout rate (including
those lost to follow-up) and the acceptability of the trial as
a process to surgeons and patients (by way of qualitative
interviews). The combination of the primary and second-
ary objectives will be used in a power calculation and to
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with longer follow-up.Patient recruitment
Patients will be screened and recruited by three consult-
ant foot and ankle orthopaedic surgeons from outpatient
clinics (in the East Lancashire Hospitals NHS Trust)
after confirmation of diagnosis and eligibility (see Table 1).
Screening will continue until the target sample size is
reached (15 patients in each arm). The number of patients
to be recruited has been based on discussions with the trial
statistician. There is no published data using the MOXFQ
tool to assess differences between PPH and arthrodesis.
Therefore, a power calculation was not performed.
Patients who meet the eligibility criteria will be pro-
vided with a patient information sheet and given 1 to
2 weeks to go over this information. If agreeable, in-
formed consent for entry into the trial will be obtained
from patients before randomisation is performed. Ran-
domisation will be performed using a random computer
generated sequence with a 1:1 allocation ratio in blocks
of six. The online website Sealed Envelope [22] has been
used to do this. Allocation concealment will be ensured
by using a locked spreadsheet, which will only reveal the
allocated treatment arm after a patient’s hospital number
and study number have been entered. Given the nature
of surgical procedures, the only person involved in this
trial who will remain blinded to treatment arm alloca-
tion is the statistician. Surgeons and patients cannot be
blinded to the treatment arm. The outcome measures
used in this study are all patient administered and there-
fore this study does not require a blinded assessor.Interventions
Surgery will be performed by one of the three consultant
orthopaedic foot and ankle surgeons who are FRCSTable 1 Eligibility criteria
Inclusion Exclusion
1. Coughlin grade 3 to 4 hallux
rigidus with near constant pain
and stiffness at least at extremes
of passive motion +/− mid range
of motion pain, where conservative
treatment measures have failed
Inflammatory arthritis
Active infection
Severe vascular or neurological
deficit affecting the lower
limbs
Hallux valgus angle >15°
Inadequate or poor quality
bone stock
2. Aged 45 years or above Any previous surgery to the first
MTPJ other than a cheilectomy
3. Male or female
4. Able to give informed consent Significant and symptomatic
interphalangeal joint or
sesamoid-metatarsal osteoarthritis(Trauma & Orthopaedics) qualified and on the General
Medical Council’s Specialist Register.
Arthrodesis arm
The procedure will be carried out under either general
or regional anaesthesia as directed by the anaesthetist
and patient. A local anaesthetic ankle block to the tibial,
saphenous, deep and superficial peroneal nerves will be
administered prior to the start of the procedure using
20 ml 0.5% bupivicaine. The first MTPJ will be exposed
through a longitudinal dorsal or medial skin and capsular
incision and the joint surfaces will be prepared, arthro-
desed in 10° of dorsiflexion and held with two crossed
headless compression screws. Post-operatively the patients
will be mobilised in a wedge shoe for 6 weeks.
Hemiarthroplasty arm
The hemiarthroplasty device used will be the AnaToe-
mic PPH (Arthrex Ltd., Sheffield, UK) The same surgical
approach as used for the arthrodesis group will be
employed. Adhesions between the sesamoids and the
metatarsal head will be released and osteophytes excised.
The component will be inserted uncemented as per the
manufacturer’s guidelines, including carrying out a chei-
lectomy if required to ensure a minimum arc of motion
of 80° is achieved. Active and passive mobilisation will
be commenced on the second day post-operatively, and
a wedge shoe will be worn for 6 weeks. Following this
period, these patients will have physiotherapy aimed at
increasing the range of motion of the joint.
Data collection
The primary outcome measure, the MOXFQ, was chosen
as it is a validated, patient-reported, foot and ankle ques-
tionnaire. It comprises 16 questions and is represented by
three domains (walking/standing, pain and social inter-
action). The MOXFQ has been shown to be reliable, valid,
responsive and acceptable in validation studies [23,24].
The AOFAS-Hallux score comprises three areas: pain,
function and alignment. This is a clinician-administered
questionnaire, scored out of 100. The question relating
to MTPJ range of motion will be removed for all pa-
tients in both treatment arms post-operatively. This is
because the arthrodesis treatment arm will automatically
score 0 for this (an arthrodesis by definition is a fused
joint). Therefore, post-operative AOFAS-Hallux scores
will be scored out of 90. The AOFAS score is very popu-
lar for reporting foot and ankle outcomes. However, it
does not have extensive or rigorous supporting validation
studies. Baumhauer et al. [25] raised concerns regarding
this score’s reliability and validity in the activity subscale.
Ibrahim et al. [26] reported satisfactory reliability and re-
sponsiveness with acceptable validity at best. For this
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mary outcome measure.
The EuroQol EQ-5D-5 L is a standardised measure of
health status [27]. It comprises five dimensions (anx-
iety/depression, mobility, self-care, usual activities and
pain/discomfort) and each dimension has five levels of
patient-reported severity. When referenced to population-
standardised datasets, this provides a health status index
value. A visual analogue score for perceived health state
makes up the second part of the EQ-5D-5 L.
Trial data will be collected using a structured data
collection form, which will include basic patient demo-
graphic details and all relevant study questionnaires.
These will be completed in paper format. All patient
trial paperwork will be stored in individual files in a se-
cure, locked cabinet in the Research & Development
main office. Data fields will be checked for completeness
and entered into a secure password-protected spread-
sheet. This will be stored on a Trust approved, encrypted
USB stick and kept locked along with the Trial Site File
and patient trial folders.
For all patients, basic demographic data will be re-
corded following trial consent and randomisation. Out-
come scores (MOXFQ, AOFAS and EQ-5D-5 L) will be
completed preoperatively and then post-operatively (see
Table 2). Details regarding length of hospital stay, return
to work, complications and any episodes of repeat sur-
gery will also be collected.
At the 12-month follow-up, patients will additionally
have a short structured interview with the research


















Radiological reviewa whole, the acceptability of the randomisation process
and any aspects that could be improved. The operating
surgeons (both senior authors) will also undergo similar
structured interviews at the conclusion of the trial. This
qualitative data will be collated and used to determine
what areas of the trial design and conduct need to be ad-
dressed before embarking on a larger prospective multi-
centre randomised control trial.
Statistical methods
The primary analysis will compare MOXFQ scores be-
tween the two treatment groups at 12 months using a t-
test, adjusting for the score at baseline. A similar analysis
will be carried out to investigate differences in secondary
outcomes (AOFAS-Hallux and EQ-5D-5 L) between the
two treatment groups. Effect sizes will be presented as a
point estimate, 95% confidence intervals and P values.
Rates of patient dropout will be reported at each time
point. The observed effect size will be used in a power
calculation for a future definitive trial.
Ethics and dissemination
This study will be conducted in accordance with the
current revision of the Declaration of Helsinki (1996)
and the ICH-GCP Guideline (International Conference
on Harmonisation, Good Clinical Practice, E6(R1), 1996).
The research protocol, patient information sheets and trial
consent forms have been reviewed and approved by the
sponsor, the Trust Research & Development office. Ethical
approval has been received from the National Research
Ethics Service (North East: 12/NE/0385 for protocolervention and assessment
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tered as a controlled trial (ISRCTN: 88273654) [28].
We aim to publish one main trial outcome paper from
this study and present the results at appropriate na-
tional and international orthopaedic conferences. The
data from this study will hopefully provide a range of
changes in outcome measures, which will then allow a
power calculation. Together with data collected on pa-
tient accrual rate, dropout rate and trial acceptability (to
patients), we aim to develop a larger prospective rando-
mised controlled trial (possibly multi-centre based) with
longer follow-up.
Trial status
The trial is currently recruiting participants.
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